later read abbott
like gain bp us share quarter
pt three consecut quarter share gain
suggest improv execut share gainer
perform incumb threat
primari stock catalyst
take stock know far like gain bp us
market share quarter abbott us result yesterday
preliminari result indic like gain bp
us market share know
revenu preliminari neuromodul result earlier month
estim assum half boston upsid
versu estim came us us
busi flat instead declin model given posit
commentari around intelli would suggest gain bp share
quarter pleas see exhibit updat market model follow
abbott clear momentum higher share base grew faster
quarter y/i sequenti abbott us growth repres
pt sequenti comp-adjust acceler notabl given burst
fda approv octob anniversari quarter howev
us busi grew faster also note abbott us
sequenti q/q growth lower
gain share three consecut quarter indic execut may
improv gain bp us share impli
compani end quarter us market share annual
basi would share pt increas fail
gain share gain share three consecut quarter
bp bp like bp execut improv
follow new sale leadership help creat favor outlook
market model current suggest gain addit pt
annual share us share
nan year re-affirmed senza clinic superior discuss
nan report despit variou attempt multipl clinic commerci
set discredit nevro senza devic abbott sunburst boston
whisper singl random data set rival
efficaci durabl senza-rct data matter could
gain meaning share without admittedli import data
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
binari sector intervent cardiolog incumb
set unveil addit data respect platform nan
name trial boston verita studi
singl arm studi like two senza-pdn senza-nsrbp
next year incumb threat legitim abil
gain share face increas competit primari driver share
price perform prior increas visibl clinic catalyst
updat model pre-announce updat model
pre-announce model revenu vs guidanc
reflect growth rate prior higher
finish top-line guidanc look achiev us given growth
us estim ou estim reflect
growth respect continu see take share year
differenti hf therapi better execut new sale leadership
expect addit disclosur around expans initi later year
million
accret redeem convert prefer stock redempt valu
dollar million except per share data
good sold
dollar million except per share data
dollar million except per share data
accumul comprehens loss
dollar million except per share data
non-cash loss extinguish debt
payment origin issu discount
provis doubt account
write-down inventori
unreal loss foreign currenc transact
purchas short-term invest
proce matur short-term invest
chang restrict cash
proce issuanc common stock underwritten public offer
proce issuanc convert note
convert note initi issuanc discount debt issuanc costs-
proce issuanc warrant
purchas convert note hedg
repay debt
purchas common stock proce issuanc common stock stock option exercis
begin period
end period
price target base multipl base case
ep peer histor premium see
multipl reflect abbott better peer top bottom line growth nutrit
recov china imf headwind fade aler stabil gradual return market
growth new product libr confirm mri heartmat launch
acceler organ growth management execut deal synergi margin
valu driver includ continu oper margin expans core abbott
combin cost synergi execut st jude aler organ growth
acceler driven devic product launch diabet ep heart failur
risk price target includ emerg market macro slowdown fx headwind
strengthen us dollar failur deliv synergi target and/or growth
acceler st jude aler
price target base multipl base case
ep assum trade peer slightli peer averag multipl
justifi superior emerg growth leverag profil
risk price target includ unfavor legal develop increas competit
core de market competit product launch failur execut
plan pipelin program
price target deriv ep reflect turn
discount larg cap peer given recent execut disconnect compani still abl
produc high singl digit low doubl digit bottom line growth constant currenc
profil driven covidien synergi underli leverag debt paydown
share repurchas
risk price target includ materi chang competit landscap
db tavr dcb linq ii slowdown emerg market iii less
repurchas activ materi acquisit
price target deriv dcf valuat equat
ev/sal assum ww termin share margin wacc
yield add expans reach
equat sale
risk price target includ competitor product sale strategi hamper
abil gain share ii current rep/physician relationship stronger
anticip iii confid ip posit patent litig may key risk
time iv potenti boston at-risk launch
